freephone 0800 862 0373
Sign in to view your quotes
Email address:
Password or PIN:

Forgotten your password? Reset it here.

New drug treats rare form of lung cancer

Published on 04/12/2012

A new drug to treat a rare form of lung cancer could soon be available to treat private health insurance patients, after showing promise in early trials.


New drug crizotinib treats a rare form of lung cancer

Non-small cell lung cancer is the most common form of lung cancer. About five per cent of sufferers have an overactive protein called ALK that can stimulate cancer cells to grow.

Patients with the overactive protein are typically younger than average, and their form of lung cancer is not closely linked to smoking.

But a new drug called crizotinib has been given an early license after successfully blocking the overactive ALK protein.

Crizotinib, marketed as Xalkori, is the latest in a new generation of cancer drugs tailored to individuals with specific genetic make-ups. Patients who can benefit from the drug are identified by analysing tissue samples.

In the latest study of 347 lung patients, the drug doubled the time taken for treated tumours to start growing again or stop shrinking.

In addition, patients taking Crizotinib had a progression-free survival of 7.7 months, compared with three months for those on standard chemotherapy.

Whilst long-term survival rates on the drug have not been studied, researchers believe it has the potential to extend lives.

Dr Ekaterini Boleti, a member of the trial team from the Royal Free Hospital, London, said: “It's not a miracle drug, but it's a huge leap forward.

“We see this as the beginning of a new era of cancer treatment... [that is] much more targeted and personalised.”

Crizotinib is likely to receive a full license after all trial data has been processed. Once the drug is licensed in the UK, it will be covered by a number of leading health insurers like Bupa and Aviva.

However, the drug will have to be assessed and deemed cost effective by the National Institute for Health and Clinical Excellence before being made widely available in the UK.

© ActiveQuote Ltd. 2012


Categories:  Medical
New drug treats rare form of lung cancerA new drug to treat a rare form of lung cancer could soon be available to treat private health insurance patients, after showing promise in     tweet it on twittershare with your friends on Facebookshare with your friends on MySpaceBlog it on your LinkedIn profile
 

No.1 health insurance broker as rated by customers

Excellent service. Explained everything in detail and really helped to find the right insurance best suited to my needs - which wasn't necessarily the most expensive. 

Review centre member

Good value and the advisor was very helpful and recommended the best policy for my grandson. I would definitely use this service again and recommend to others.

Review centre member

We were contacted in good time to make a knowledgable choice. We were given plenty of options with lots of information to enable us to make the right choice.

Review centre member

The service I received was excellent, the staff member was very efficient and knowledgable. She went out of her way to get the best policy for me.

Review centre member

Great service. I really appreciated the help provided by Active Quote to arrange health insurance. The agent was very informative and proactive. Many thanks!

Review centre member

I received excellent care and attention from the first phone call till the last. Friendly, efficient and patient.

Review centre member

Staff are very helpful, friendly and polite. They call back when they say they will and keep you up to date with progress. Pleasure to deal with.

Review centre member

Very polite and friendly, and gave detailed explanations of all aspects of the cover. Reassuring to know that if you do have a problem there is someone you can contact.

Review centre member

Friendly and efficient. Nothing was too much trouble even when i needed to make a small change, excellent service.

Review centre member

The advisor was incredibly helpful and fully explained the differences between the policies. I really liked the fact that I was put under no pressure.

Review centre member
 
This site is operated by Insurance Broker ActiveQuote Ltd registered in England & Wales company number 6765845.
Authorised and Regulated by the Financial Conduct Authority (FCA). Firm reference number 501109 as detailed on the Financial Services Register. Please read our Key Facts document.
For information about your rights as a consumer visit Citizens Advice.

Our insurance comparison service is free and easy for you to use, but you are responsible for making sure all your information is entered correctly, and for choosing your insurer.

This site uses cookies in order to work correctly - these are not harmful and do not contain personal information. By using this site you consent to this. I understand  Tell me more

please wait ...